首页> Clinical genitourinary cancer> Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools.

Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools.

导出 LinkOut

翻译打印收藏纠错

第一作者： Michelle R,Downes

第一单位： Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Precision Diagnostic & Therapeutic Program, Toronto, Ontario, Canada. Electronic address: michelle.downes@sunnybrook.ca.

作者： Michelle R,Downes ^[1] ; Kristen N,Liu ^[2] ; Yanhong,Yu ^[3] ; Katherine,Lajkosz ^[4] ; Lisa J,Kroon ^[5] ; Eva,Hollemans ^[5] ; Neil,Fleshner ^[6] ; Antonio,Finelli ^[7] ; Geert J L H,van Leenders ^[5] ; Kenneth A,Iczkowski ^[2] ; Theodorus H,van der Kwast ^[8]

作者单位： Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Precision Diagnostic & Therapeutic Program, Toronto, Ontario, Canada. Electronic address: michelle.downes@sunnybrook.ca. ^[1] Department of Pathology, Medical College of Wisconsin, Milwaukee, WI. ^[2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. ^[3] Department of Biostatistics, Princess Margaret Hospital, Toronto, Ontario, Canada. ^[4] Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. ^[5] Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada. ^[6] Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre-University Health Network, Toronto, Canada. ^[7] Laboratory Medicine Program, University Health Network and Princess Margaret Cancer Centre, Toronto, ON, Canada. ^[8]

关键词 Biochemical recurrence Cribriform pattern Event free survival Outcome